Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.

Perry R, Kipps C, Soto Martín ME, Bozzali M, Logroscino G, Trafford S, Dhadda S, Kanekiyo M, Goodwin A, Hodgkinson M, Hersch S, Irizarry M, Kramer L, Froelich L

Open source

DOI: 10.1016/j.tjpad.2026.100507
Published: 2026 Apr
Container: The journal of prevention of Alzheimer's disease
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.tjpad.2026.100507,
  title = {Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.},
  author = {Perry R and Kipps C and Soto Martín ME and Bozzali M and Logroscino G and Trafford S and Dhadda S and Kanekiyo M and Goodwin A and Hodgkinson M and Hersch S and Irizarry M and Kramer L and Froelich L},
  year = {2026},
  journal = {The journal of prevention of Alzheimer's disease},
  doi = {10.1016/j.tjpad.2026.100507},
  url = {https://doi.org/10.1016/j.tjpad.2026.100507}
}

RIS

TY  - JOUR
TI  - Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.
AU  - Perry R
AU  - Kipps C
AU  - Soto Martín ME
AU  - Bozzali M
AU  - Logroscino G
AU  - Trafford S
AU  - Dhadda S
AU  - Kanekiyo M
AU  - Goodwin A
AU  - Hodgkinson M
AU  - Hersch S
AU  - Irizarry M
AU  - Kramer L
AU  - Froelich L
PY  - 2026
JO  - The journal of prevention of Alzheimer's disease
DO  - 10.1016/j.tjpad.2026.100507
UR  - https://doi.org/10.1016/j.tjpad.2026.100507
ER  -

APA

R, P., C, K., ME, S. M., M, B., G, L., S, T., S, D., M, K., A, G., M, H., S, H., M, I., L, K., & L, F. (2026). Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.. The journal of prevention of Alzheimer's disease. https://doi.org/10.1016/j.tjpad.2026.100507

Source records

pubmed · retrieved 2026-09-25T11:15:02.432Z
europe-pmc · retrieved 2026-09-25T11:15:02.446Z
doaj · retrieved 2026-09-25T11:15:02.405Z